Century Therapeutics, Inc.(IPSC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Century Therapeutics, Inc. (IPSC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IPSC at 33.5/100 on a 32-signal composite quality model, placing it at rank #2,388 of 2,962 stocks — the bottom half of the AI-ranked universe. IPSC scores in the top quartile across revenue growth (99.3), institutional flow (92.6). Areas of concern include balance sheet strength (5.5) and free cash flow (7.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Century Therapeutics, Inc. reports net income of $-34.5M, free cash flow of $-20.5M. Top institutional holders of IPSC by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, Versant Venture Management, based on the most recent SEC filings. IPSC trades on the Nasdaq exchange and files with the SEC under CIK 1850119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Century Therapeutics, Inc. directly from SEC EDGAR.